Glenmark's interim data from PMS Study on Favipiravir released
The study was conducted in patients with mild to moderate COVID-19
The study was conducted in patients with mild to moderate COVID-19
PegIFN in COVID19 has several add-on advantages compared to other anti-viral agents
Viruses evolve into new strains when there is a change to their genetic composition.
Subscribe To Our Newsletter & Stay Updated